Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.55 -1.93%

-$0.64 today

Market cap
$2.21B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.39M

Average 0.31M

PHVS Debt Repayment

Cash used to repay borrowings during the period.

Pharvaris N.V.NASDAQ: PHVS

Debt Repayment · Q3 FY2026 · quarter ended Sep 2026

Debt repayment growth accelerates

Q3 FY2026 debt repayment of €62.44K (cash outflow) rose 150.8% year over year, ahead of the +6.4% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.

Context

  • Debt repayment grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +150.8% holds above the trailing-twelve-month pace of +6.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-€62.44K+0.6% QoQ
Last fiscal yearDec 2025
-€219.01K+37.2% YoY
LTMSep 2026
-€190.79K+6.4% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+150.8%——
1 year+37.2%——
3-year CAGR+22.4%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

EUR · from the cash flow

Latest · FY2025
(219.01K) EUR
Year-over-year change
-37.2%

Debt Repayment vs competitors

How PHVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.4% is the 3rd highest of 4, against a peer median of +310.8%.
  • Over three fiscal years its annual growth of +22.4% compares with a peer median of +5.6%.
PHVS Competitors
Debt Repayment for PHVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$3.65B USD——0.4%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$174.12M USD+352.7%—26.7%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$150.65M USD+310.8%—16.0%
PHARPharming Group N.V.LTM Mar 2026$1.07M USD-96.7%—0.3%
PHVSPharvaris N.V.LTM Sep 2026€190.79K EUR+6.4%+22.4%—
VERAVera Therapeutics, Inc.LTM Jun 2026$0 USD—+5.6%—
RLYBRallybio CorporationLTM Mar 2026$0 USD——0.0%
Peer median (excluding PHVS) —+310.8%+5.6%0.4%

Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.66M)(75.65M)(99.83M)(132.4M)(173.71M)
Depreciation & Amortization77.37K152.94K257.55K269.56K418.35K
Deferred Income Tax00000
Stock-Based Compensation8.2M11.35M10.66M16.21M19.05M
Change in Working Capital1.58M8.38M(5.86M)5.89M7.62M
Accounts Receivables(130.5K)317.61K(41.05K)(34.32K)(331.34K)
Inventory00000
Accounts Payables00000
Other Working Capital1.71M8.06M(5.82M)5.92M7.96M
Other Non-Cash Items(11.79M)(11.39M)1.72M(10.1M)9.54M
Operating Cash Flow(44.6M)(67.16M)(93.05M)(120.13M)(137.07M)
Capital Expenditures(130.03K)(124.3K)(89.98K)(538.09K)(164.62K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(130.03K)(124.3K)(89.98K)(538.09K)(164.62K)
Debt Repayment0(119.53K)(220.51K)(159.66K)(219.01K)
Common Stock Issued156.83M9.61M342.91M2.24M171.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(13.15M)(839.97K)(17.3M)592K(10.91M)
Financing Cash Flow143.67M8.65M325.39M2.68M160.61M
Effect of Forex Changes11.78M11.12M(2.86M)7.49M(12.42M)
Net Change in Cash110.72M(47.52M)229.39M(110.5M)10.95M
Free Cash Flow(44.73M)(67.29M)(93.14M)(120.67M)(137.24M)

Pharvaris N.V.

NASDAQ:PHVS

Intrinsic Alpha fair value

Locked

Current Price

$31.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.